SuperworthMoonLake Immunotherapeutics shares outstanding MLTX
Diluted shares outstanding, averaged over each quarter, from 2021.
- Latest quarter, to Jun 30, 2026
- 73.9M
- On a year earlier
- +16.8%
- more shares
MoonLake Immunotherapeutics had 73.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 16.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 67.9M | +8% |
| FY2024 | 63.1M | +5% |
| FY2023 | 59.9M | +50% |
| FY2022 | 39.8M | +139% |
| FY2021 | 16.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 73.9M | +17% | |
| Q1 FY26 | 71.3M | +13% | |
| Q4 FY25 | 67.9M | +8% | |
| Q3 FY25 | 63.4M | +1% | |
| Q2 FY25 | 63.3M | +1% | |
| Q1 FY25 | 63.2M | +1% | |
| Q4 FY24 | 63.1M | +5% | |
| Q3 FY24 | 62.9M | +18% | |
| Q2 FY24 | 62.9M | +44% | |
| Q1 FY24 | 62.6M | +60% | |
| Q4 FY23 | 59.9M | +50% | |
| Q3 FY23 | 53.5M | +45% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on MoonLake Immunotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.